GlassScriptPhysician profile
Anay Castro
NPI 1881720845
$18,020.89
in general payments reported to CMS, 2019-2025
26 companies · $2,972 in 2025
The $2,972 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,063 · 2022: $3,656 · 2023: $4,077 · 2024: $5,253 · 2025: $2,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,513 · Education: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,132.31 |
| Consulting Fee | $1,512.50 |
| Education | $656.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,503.48 | 2021-2025 | |
| Janssen Biotech, INC. | $2,193.91 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $1,705.72 | 2021-2025 | |
| Leo Pharma INC. | $1,675.78 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,609.68 | 2021-2025 | Dupixent |
| Pfizer INC. | $1,376.30 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,069.47 | 2022-2025 | Sotyktu |
| Amgen INC. | $778.01 | 2021-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $757.97 | 2021-2025 | Ilumya, Winlevi, Odomzo |
| Ucb, INC. | $602.95 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $587.42 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $556.78 | 2022-2024 | Vtama |
| Lilly USA, LLC | $497.85 | 2022-2025 | Taltz, Olumiant, Zepbound |
| Galderma Laboratories, L.P. | $359.79 | 2021-2025 | Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $184.31 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $163.95 | 2022-2024 | |
| Merz North America, INC. | $97.78 | 2021 | |
| Incyte Corporation | $89.97 | 2021-2023 | Opzelura |
| Mayne Pharma Commercial LLC | $50.33 | 2021-2022 | |
| Revance Therapeutics, INC. | $33.27 | 2024-2025 | Daxxify |
| Epi Health, LLC | $23.83 | 2021 | |
| Genentech USA, INC. | $22.78 | 2023 | Xolair |
| Journey Medical Corporation | $22.43 | 2023 | |
| Vyne Pharmaceuticals INC. | $21.52 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.36 | 2023 | Spevigo |
| Organon LLC | $15.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anay Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.